Press releases

Orchard Therapeutics Receives EMA PRIME Designation for OTL-300, an Investigational Lentiviral Gene Therapy for the Treatment of Transfusion-Dependent Beta-Thalassemia

Orchard Therapeutics today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to OTL-300, an investigational autologous ex vivo lentiviral gene therapy for the treatment of transfusion-dependent beta-thalassemia (TDBT), the most severe form of beta-thalassemia.

Read more

Orchard Therapeutics Expands Leadership Team with Appointments of Head of Corporate Communications and Head of Human Resources

Orchard Therapeutics today announced two additions to its executive leadership team, appointing Kathryn (Katie) Payne as senior vice president, global head of corporate communications and external affairs, and John Cerio as senior vice president, global head of human resources

Read more

Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline

Proceeds to advance three late-stage programs towards registration, prepare for commercialization and progress the company’s gene therapy platform

Read more

Orchard Therapeutics Appoints Jon Ellis to Board of Directors

Orchard Therapeutics today announced the appointment of Jon Ellis, Ph.D. as GSK’s designated representative to its board of directors. Dr. Ellis is currently vice president and head of science & technology licensing at GlaxoSmithKline (GSK)

Read more

Orchard Therapeutics Appoints Joanne Beck, Ph.D. to Board of Directors

Orchard Therapeutics today announced the appointment of Joanne Beck, Ph.D., to its board of directors. Dr. Beck is currently the executive vice president of pharmaceutical development and operations and a member of the executive committee at Celgene

Read more